96 related articles for article (PubMed ID: 9178528)
1. Synthesis and biological evaluation of 7-hydroxy-3,4-diphenyl-1,2-dihydroisoquinolines as new 4-hydroxytamoxifen analogues.
Kihara M; Ikeuchi M; Yamauchi A; Nukatsuka M; Matsumoto H; Toko T
Chem Pharm Bull (Tokyo); 1997 May; 45(5):939-43. PubMed ID: 9178528
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of 3,4-diphenyl-1,2-dihydroisoquinolines as a new tamoxifen analogue.
Kihara M; Ikeuchi M; Nagao Y
Drug Des Discov; 1995 Jan; 12(3):259-71. PubMed ID: 7662832
[TBL] [Abstract][Full Text] [Related]
3. Carboxylic acid analogues of tamoxifen: (Z)-2-[p-(1, 2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine. Estrogen receptor affinity and estrogen antagonist effects in MCF-7 cells.
Kraft KS; Ruenitz PC; Bartlett MG
J Med Chem; 1999 Aug; 42(16):3126-33. PubMed ID: 10447957
[TBL] [Abstract][Full Text] [Related]
4. 6-Alkyl-12-formylindolo[2,1-a]isoquinolines. Syntheses, estrogen receptor binding affinities, and stereospecific cytostatic activity.
Polossek T; Ambros R; von Angerer S; Brandl G; Mannschreck A; von Angerer E
J Med Chem; 1992 Sep; 35(19):3537-47. PubMed ID: 1404234
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and characterization of fluorescent 4-hydroxytamoxifen conjugates with unique antiestrogenic properties.
Rickert EL; Oriana S; Hartman-Frey C; Long X; Webb TT; Nephew KP; Weatherman RV
Bioconjug Chem; 2010 May; 21(5):903-10. PubMed ID: 20420372
[TBL] [Abstract][Full Text] [Related]
6. Nonisomerizable analogues of (Z)- and (E)-4-hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes.
McCague R; Leclercq G; Jordan VC
J Med Chem; 1988 Jul; 31(7):1285-90. PubMed ID: 3385723
[TBL] [Abstract][Full Text] [Related]
7. Antiestrogen basicity--activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-butene (tamoxifen, Nolvadex) having altered basicity.
Robertson DW; Katzenellenbogen JA; Hayes JR; Katzenellenbogen BS
J Med Chem; 1982 Feb; 25(2):167-71. PubMed ID: 7057423
[TBL] [Abstract][Full Text] [Related]
8. Hydroxy derivatives of tamoxifen.
Foster AB; Jarman M; Leung OT; McCague R; Leclercq G; Devleeschouwer N
J Med Chem; 1985 Oct; 28(10):1491-7. PubMed ID: 4045924
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution of 123I-labeled 4-hydroxytamoxifen derivatives in rats with dimethylbenzanthracene-induced mammary carcinomas.
Kruijer PS; Klok RP; van den Koedijk CD; Blankenstein MA; Voskuil JH; Verzeijlbergen JF; Ensing GJ; Herscheid JD
Nucl Med Biol; 1997 Nov; 24(8):719-22. PubMed ID: 9428596
[TBL] [Abstract][Full Text] [Related]
10. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
11. Antiestrogenic effects of Z-1, 1-dichloro-2,3 diphenyl-2-(4-methoxyphenyl)cyclopropane(5a) on human breast cancer cells in culture.
Jain PT; Pento JT; Magarian RA
Anticancer Res; 1992; 12(3):585-90. PubMed ID: 1622114
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel tamoxifen analogues.
Christodoulou MS; Fokialakis N; Passarella D; García-Argáez AN; Gia OM; Pongratz I; Dalla Via L; Haroutounian SA
Bioorg Med Chem; 2013 Jul; 21(14):4120-31. PubMed ID: 23735829
[TBL] [Abstract][Full Text] [Related]
13. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
Devulapally R; Sekar TV; Paulmurugan R
Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
[TBL] [Abstract][Full Text] [Related]
14. 3,4-bis(3'-hydroxyphenyl)hexane--a new mammary tumor-inhibiting compound.
Kranzfelder G; Hartmann RW; von Angerer E; Schönenberger H; Bogden AE
J Cancer Res Clin Oncol; 1982; 103(2):165-80. PubMed ID: 6284766
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of novel N-substituted N'-(3-hydroxy-17-oxoestra-1,3,5(10)-trien-2- and -4-yl)thiourea derivatives for binding to the estrogen receptor and cytotoxic activity on MCF-7 cells.
Omar AM; Aboulwafa OM; Leclercq G
J Pharm Sci; 1984 Dec; 73(12):1871-3. PubMed ID: 6441843
[TBL] [Abstract][Full Text] [Related]
16. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
Lee ES; Schafer JM; Yao K; England G; O'Regan RM; De Los Reyes A; Jordan VC
Clin Cancer Res; 2000 Dec; 6(12):4893-9. PubMed ID: 11156249
[TBL] [Abstract][Full Text] [Related]
17. The anti-estrogen hydroxytamoxifen is a potent antagonist in a novel yeast system.
Liu JW; Jeannin E; Picard D
Biol Chem; 1999 Nov; 380(11):1341-5. PubMed ID: 10614829
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, tumor inhibitory and antioxidant activity of new polyfunctionally 2-substituted 5,6,7,8-tetrahydronaphthalene derivatives containing pyridine, thioxopyridine and pyrazolopyridine moieties.
Hamdy NA; Anwar MM; Abu-Zied KM; Awad HM
Acta Pol Pharm; 2013; 70(6):987-1001. PubMed ID: 24383322
[TBL] [Abstract][Full Text] [Related]
19. Loss of antagonistic activity of tamoxifen by replacement of one N-methyl of its side chain by fluorinated residues.
Agouridas V; Laïos I; Cleeren A; Kizilian E; Magnier E; Blazejewski JC; Leclercq G
Bioorg Med Chem; 2006 Nov; 14(22):7531-8. PubMed ID: 16870452
[TBL] [Abstract][Full Text] [Related]
20. Syntheses and antitumor targeting G1 phase of the cell cycle of benzoyldihydroisoquinolines and related 1-substituted isoquinolines.
Bermejo A; Andreu I; Suvire F; Léonce S; Caignard DH; Renard P; Pierré A; Enriz RD; Cortes D; Cabedo N
J Med Chem; 2002 Nov; 45(23):5058-68. PubMed ID: 12408717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
